MANIPALHOSHealthcare

Manipal Health Enterprises Limited

Hospital · ISIN INE459N01021 · BSE 544847 · NSE EQ · FV ₹2
Last price
₹647
-1.61%today
What this company does

Manipal Health Enterprises Limited operates in Hospital, part of the Healthcare sector. It booked ₹3,091 cr of revenue in its latest quarter (Q1 FY27) and kept 7.5% of sales as profit. It is the 3rd largest of 9 Hospital companies we track, by market value.

30out of 100
Equitytale Health Score
Strained

Healthier than 30% of companies in Healthcare, on the 4 of 6 measures we could read for it. Each measure is ranked against the 37–154 companies that reported it.

Measures financial condition, not whether to buy. Learn what this score means · How this is calculated

Price momentum
neutral
RSI (14)
46

At close. Not part of the score.

Profitability & returns34

How much profit it earns on the money it employs

Balance sheet15

How much it owes, and whether earnings cover the interest

Valuation15

What today's price implies, against our models or its peers

Governance & risk72

How much of the promoters' stake is pledged, and how much they hold

Not measurable for this company: cash quality, growth & consistency. Those pillars are left out of the score rather than counted as zero.

Is this company doing well?
not investment advice
Strengths
✓ Makes a profit
✓ Promoters hold 72%
Watch-outs
! Thin 7.5% net margin
! 8.5% of promoter stake pledged

What if I invest in MANIPALHOS?

Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.

You would put in
₹12.00 lakh
120 instalments
At 10% a year, it would become
₹20.15 lakh

The starting rate is a round number, not a view on this company — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.

Key ratios · latest quarter + price
₹647▼ -1.61%
latest close · 2026-11-06
52-wk low ₹59765 sessions so far52-wk high ₹815
Is it cheap or expensive?
What you pay for the profits, book value and cash flow. Higher isn't automatically worse — it can signal faster growth.
P/E ratio82.5High
LowAverageHigh
How good is the business?
How much profit it earns from its money and its sales.
Net margin7.5%Decent
ThinDecentStrong
EBITDA margin25.7%Healthy
ThinDecentHealthy
Is it financially safe?
How much it owes, and whether it can comfortably cover it.
Interest cover2.1×Okay
RiskyOkayStrong ▸5×
More figures
Market cap
₹76,294 cr
Book value
—
EPS
₹1.96
latest quarter
Net debt
—
Enterprise value
—
EBITDA
₹3,183 cr
annualised
EBIT
₹2,434 cr
annualised
Operating margin
19.7%
Return on assets
—
Earnings yield
1.21%
P/S
6.17
Sales / share
₹104.8
Tax rate
22.8%
Face value
₹2
Shares
118.0 cr
Working capital
—
Current assets
—
Current liabilities
—
Delivery %
56.0%
Strong / safeFairWeak / riskyValuation — a level, not good/badBands are general rules of thumb, not advice.

P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-11-06.

Worth vs price · from the exchange filings
not investment advice
Hard to value confidentlyLow confidence
We haven't parsed this company's annual profit history yet — common for banks and insurers, whose results file in a different format — so we can't value it off earnings.

An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.

P&L · Q1 FY27 (consolidated)
Revenue from Operations₹3,091 cr
Other Income₹75 cr
Total Income₹3,165 cr
Cost of Materials₹0 cr
Purchases of Stock-in-Trade₹650 cr
Inventory Change (±)₹-24 cr
Employee Benefit Expense₹462 cr
Finance Costs₹293 cr
Depreciation & Amortisation₹187 cr
Other Expenses₹1,266 cr
Total Expenses₹2,835 cr
Exceptional Items₹-15 cr
Profit before Tax₹315 cr
Tax Expense₹72 cr
Net Profit₹243 cr
Net margin on total income7.7%
Where the money goes · Q1 FY27
% of total income
Materials + stock-in-trade₹626 cr19.9%
Employee benefit expense₹462 cr14.7%
Finance costs₹293 cr9.3%
Depreciation & amortisation₹187 cr5.9%
Other expenses₹1,266 cr40.2%
Tax expense₹72 cr2.3%
Profit for the period₹243 cr7.7%
Total income ₹3,165 cradds up to ₹100 ✓
Peer comparison
Hospital · by market value
CompanyPriceMarket capP/E
Apollo Hospitals Enterprise Limited₹8,446₹1.21 L cr48.3
Max Healthcare Institute Limited₹934₹90,907 cr54.8
Manipal Health Enterprises Limitedthis company₹647₹76,294 cr82.5
Fortis Healthcare Limited₹767₹57,898 cr46.3
Narayana Hrudayalaya Ltd.₹1,903₹38,890 cr32.1
Global Health Limited₹1,388₹37,281 cr42.3
Aster DM Quality Care Limited₹713₹36,950 cr575.1
Krishna Institute of Medical Sciences Limited₹723₹30,366 cr101.0
Dr. Agarwal's Health Care Limited₹516₹16,368 cr78.2
Same industry · latest reported numbers · not a recommendation.
Who owns it · 2026-09-30
⚑ 8.5% pledged
Promoter
72.1%
FII / Foreign
3.5%
DII / Domestic
7.2%
Retail / others
17.2%
Smart-money activity
Bulk / block deals
SoldPRAZIM TRADING AND INVESTMENT COMPANY PRIVATE LIMITED · NSE18.98 L @ ₹63021 Oct 26
BoughtPI OPPORTUNITIES AIF V LLP · NSE18.98 L @ ₹63021 Oct 26
Stake changes
BoughtAxis Trustee Services ltd→ 8.86% · 11.66 cr5 Aug 26
BoughtDeutsche Bank AG Singapore Branch→ 21.78% · 28.64 cr5 Aug 26
BoughtVistra ITCL (India) Limited→ 28.06% · 36.90 cr5 Aug 26
Promoter pledges
PledgedManipal Global health Services23.21 cr · 0.00% held5 Aug 26
What shareholders were asked to approve
4 proposals passed only on promoter votes

A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.

Yearly shareholder meeting · 29 Sep 2026
See the official result
1
To consider and adopt the standalone and consolidated financial statements for the Financial Year ended March 31, 2026, and the reports of the auditors and Board of Directors Thereon
Backed by 100% of shareholders other than promotersneeded 50%
25.36 cr votes for, 583 against · 0% of mutual funds and other big investors said no
2
To appoint a Director in place of Dr. Hebri Sudarshan Ballal (DIN: 01195055), who retires by rotation and being eligible, offers himself for re-Appointment.
Backed by 91% of shareholders other than promotersneeded 50%
22.98 cr votes for, 2.38 cr against · 0% of mutual funds and other big investors said no
3
To appoint a Director in place of Mr. Puneet Bhatia (DIN: 00143973), who retires by rotation and being eligible, offers himself for re-appointment.
Backed by 100% of shareholders other than promotersneeded 50%
25.35 cr votes for, 1.71 L against · 0% of mutual funds and other big investors said no
4
To appoint Price Waterhouse Chartered Accountants LLP (PWC), Chartered Accountants as the Statutory Auditors of the Company.
Backed by 100% of shareholders other than promotersneeded 50%
25.36 cr votes for, 997 against · 0% of mutual funds and other big investors said no
7
Approval and ratification of the Manipal Health Enterprises Employee Stock Option Plan 2024 ("ESOP 2024 Plan") within the meaning of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.
⚑ Passed only because promoters voted yes
Backed by 69% of shareholders other than promotersneeded 75%
17.41 cr votes for, 7.95 cr against · 0% of mutual funds and other big investors said no
8
Ratification of the extension of benefits under the "Manipal Health Enterprises Employee Stock Option Plan 2024" to the eligible employees of the subsidiaries and group companies of the Company.
⚑ Passed only because promoters voted yes
Backed by 69% of shareholders other than promotersneeded 75%
17.39 cr votes for, 7.97 cr against · 0% of mutual funds and other big investors said no
9
Consideration and approval of the Upside Sharing Arrangement pursuant to the Upside Sharing Agreement dated March 16, 2026, entered into between Manipal Research & Management Services International and TPG SG Magazine Pte. Ltd.
⚑ Passed only because promoters voted yesPromoters had a personal stake in this
Backed by 38% of shareholders other than promotersneeded 50%
4.10 cr votes for, 6.69 cr against · 0% of mutual funds and other big investors said no
10
Approval of amendments to the Articles of Association of the Company and grant of special rights of nomination/appointment and re-appointment of Directors and Executive Committee members to the Temasek Group and the MGHS Group.
⚑ Passed only because promoters voted yesPromoters had a personal stake in this
Backed by 74% of shareholders other than promotersneeded 75%
18.69 cr votes for, 6.66 cr against · 0% of mutual funds and other big investors said no

Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.

The named holders in this filing do not add up to the promoter total it states, so we are not presenting them as the promoter group.
How the stock has moved · adjusted for splits & bonuses
Data from primary exchange filings · analysis tool, not investment advice.